Alentis is a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis. They announced today the first patient dosed in a Phase 2 clinical trial of lixudebart for the treatment of organ fibrosis.
For more details, click here.
T3 Pharma, which uses live bacteria to deliver immune-modulating proteins to cancer cells, has been acquired for up to 450M Swiss francs.
More details on the BaseLaunch website.
American distributor, LiveAquaria, has launched ‘ProtoPro’ the world’s first product based on Sundew’s proprietary active: Biokos™.
More details on the Sundew website.
Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today that the US Food and Drug Administration (FDA) has granted Fast Track development program for ALE.C04 for the treatment of patients with recurrent or metastatic, CLDN1-positive HNSCC.
Details here.
NPS have announced that they have successfully completed their consultation with FDA on their high anti-oxidant purple tomato.
The company can now launch a range of purple tomato products, including fresh tomatoes and seeds for home gardeners.
See the NPS press release here.
Chosa oncology has published results from a clinical phase 2 trial of their liposomal cisplatin formulation for breast cancer using a predictive biomarker.
More details on the Chosa website.
Alentis Therapeutics has secured the investment to fund clinical programs on its two anti-Claudin-1 antibodies for organ fibrosis and CLDN1 positive tumours.
The financing will support Phase II and Phase I programs of Alentis’ lead investigational products ALE.F02 and ALE.C04 respectively as well as the CLDN1 platform development.
More details on the BaseLaunch website.
Conarium Bioworks is focused on producing melatonin, “one of the first mainstream consumer products replacing a synthetic compound with a compound that will be fully produced through biomanufacturing”.
This article from UC San Diego Today focuses on bioengineering professor (and Conarium Board member), Bernhard Palsson.
Unibio International PLC, the leading sustainable protein company, has announced that the Saudi Industrial Investment Group (“SIIG”) will invest approximately US$70 million (GBP 59 million) in Unibio.
The proceeds will be deployed to enable Unibio’s vision of feeding the world’s growing population in a sustainable way. Unibio will use the funds to roll-out new global production capacity, grow operating capabilities, and accelerate innovation and commercialisation.
More details on the Unibio website.
“This Company’s GMO Will Help Feed The World, By Being Eaten”
Coverage of the launch of the Norfolk Healthy Produce anti-oxidant-rich purple tomato.